Suven Life Sciences Limited
NSE: SUVENMarket Closed • NSE
Day range
52 week range
Suven Life Sciences Limited closed at INR282.75 (-2.13%) on volume 1.26x its 20-day average, trading 29.9% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -178.3% QoQ
2024-07-30
AGM Announced
Annual General Meeting
2023-08-02
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.03x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 30 Jul 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 02 Aug 2023 |
| 18 Oct 2022 | Rights issue | Rights 1:2 @ Premium Rs 54/- | — | 17 Oct 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 29 Jul 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 02 Aug 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 11 Sept 2020 |
| 22 Jan 2020 | Demerger | Demerger | — | 21 Jan 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 08 Aug 2019 |
| 15 Feb 2019 | Dividend | ₹1.50 / share | — | 14 Feb 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 09 Aug 2018 |
| 07 Feb 2018 | Dividend | ₹1.50 / share | — | 06 Feb 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 09 Aug 2017 |
| 09 Feb 2017 | Dividend | ₹1.00 / share | — | 08 Feb 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 04 Aug 2016 |
| 15 Mar 2016 | Dividend | ₹1.00 / share | — | 14 Mar 2016 |
| — | Dividend | ₹0.60 / share | — | 23 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1] [2]
IndiaHealthcare
Is Suven Life Sciences Limited Shariah compliant?
Suven Life Sciences Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.21%) complies with AAOIFI threshold (≤ 33%).
What is Suven Life Sciences Limited's current valuation relative to peers?
Suven Life Sciences Limited trades at a P/E of N/A compared to the sector median of 37.6x, and a Price-to-Book of 12.6x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.03x. Interest coverage is -1838.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at -9.5% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.